CAS 881681-01-2: 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate (1:1)
Formula:C17H16FN3O2S·C4H4O4
InChI:InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
InChI key:InChIKey=ROGSHYHKHPCCJW-WLHGVMLRSA-N
SMILES:S(=O)(=O)(N1C(=CC(CNC)=C1)C2=C(F)C=CC=C2)C=3C=CC=NC3.C(=C/C(O)=O)\C(O)=O
Synonyms:- 1H-Pyrrole-3-methanamine, 5-(2-fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-, (2E)-2-butenedioate (1:1)
- 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate
- 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate (1:1)
- TAK 438 monofumarate
- Tak-438
- Takecab
- Vocinti
- Vonoprazan fumarate
- Vonaprazan
- TAK438
- See more synonyms
Sort by
Found 8 products.
Vonoprazan Fumarate
CAS:Controlled ProductApplications Vonoprazan fumarate (CAS# 881681-01-2) is a useful research chemical and a ATPase potassium-competitive acid blocker. References Kondo, M.; et al.: Journal of Biomolecular Screening, 17, 177 (2012).Formula:C17H16FN3O2S·C4H4O4Color and Shape:White To Off-WhiteMolecular weight:461.463Vonoprazan Fumarate
CAS:Formula:C17H16FN3O2S·C4H4O4Color and Shape:White To Off-White SolidMolecular weight:345.39 116.07Vonoprazan Fumarate
CAS:Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion.Formula:C21H20FN3O6SPurity:≥98%Color and Shape:SolidMolecular weight:461.46Vonoprazan fumarate
CAS:Vonoprazan fumarate is a pharmaceutical compound that functions as a potassium-competitive acid blocker (PCAB), which is derived from synthetic sources. It acts by selectively inhibiting the gastric hydrogen-potassium ATPase enzyme, commonly known as the proton pump, located in the stomach lining. This mode of action results in a significant reduction in gastric acid secretion, offering a therapeutic alternative to traditional proton pump inhibitors (PPIs). Vonoprazan fumarate is primarily utilized in the management of conditions associated with excessive gastric acid production, such as gastroesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori infections. Its efficacy in rapid acid suppression makes it particularly valuable in clinical scenarios where faster onset of action is required. Additionally, its prolonged inhibitory effect, even in the presence of food, distinguishes it from conventional PPIs, enhancing patient compliance and therapeutic outcomes. Research into vonoprazan continues to explore its full potential and advantages over existing treatments for acid-related disorders.Formula:C17H16FN3O2S•C4H4O4Purity:Min. 95%Color and Shape:PowderMolecular weight:461.46 g/mol
